D1.1. Quality assurance guidelines and procedures
A set of quality assurance scientific and clinical principles to be applied in all work to be developed during the project.
D2.2. BoB biorepository of data (front end)
Deployment of a cBioPortal instance to navigate the generated data adapted to the CCE-DART clinical needs.
D4.1. Imaging standardization
Development of a pipeline for multi-scanner image data standardization, processing and radiomics feature extraction.
D4.2. Molecular standardization
Technical specifications for non-invasive molecular monitoring approaches, including decision making thresholds for specific clinical trial scenarios.
D4.3. Imaging response
Definition of new imaging and molecular markers, based on single or combination of measurements, for patient stratification and as early readouts for tumour progression and drug response.
D5.1. Predictive biomarkers
Identification of new molecular and imaging-based biomarkers with predictive value for treatment allocation.
D5.2. Emerging response markers
Definition of new markers of tumour progression and drug response based on emerging imaging and molecular profiling technologies.
D19.1. Business sustainability and exploitation plan
Development of exploitation studies for the project outcomes.
D20.1. Initial workshop
Convene Workshop 1 between academic / pharma / regulatory stakeholders and publish workshop report.
D20.2. Final workshop
Convene Workshop 2 between academic / pharma / regulatory stakeholders and publish consensus statement for the use of novel clinical trial methods in a wide range of setting.